Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rescue of the lethal scl(-/-) phenotype by the human SCL locus.
Sinclair AM, Bench AJ, Bloor AJ, Li J, Göttgens B, Stanley ML, Miller J, Piltz S, Hunter S, Nacheva EP, Sanchez MJ, Green AR. Sinclair AM, et al. Among authors: green ar. Blood. 2002 Jun 1;99(11):3931-8. doi: 10.1182/blood.v99.11.3931. Blood. 2002. PMID: 12010791 Free article.
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
Huntly BJ, Bench AJ, Delabesse E, Reid AG, Li J, Scott MA, Campbell L, Byrne J, Pinto E, Brizard A, Niedermeiser D, Nacheva EP, Guilhot F, Deininger M, Green AR. Huntly BJ, et al. Among authors: green ar. Blood. 2002 Jun 15;99(12):4547-53. doi: 10.1182/blood.v99.12.4547. Blood. 2002. PMID: 12036887 Free article.
Essential thrombocythemia.
Harrison CN, Green AR. Harrison CN, et al. Among authors: green ar. Hematol Oncol Clin North Am. 2003 Oct;17(5):1175-90, vii. doi: 10.1016/s0889-8588(03)00082-0. Hematol Oncol Clin North Am. 2003. PMID: 14560781 Review.
Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.
Kluin-Nelemans HC, Buck G, le Cessie S, Richards S, Beverloo HB, Falkenburg JH, Littlewood T, Muus P, Bareford D, van der Lelie H, Green AR, Roozendaal KJ, Milne AE, Chapman CS, Shepherd P; MRC and HOVON groups. Kluin-Nelemans HC, et al. Among authors: green ar. Blood. 2004 Jun 15;103(12):4408-15. doi: 10.1182/blood-2003-10-3605. Epub 2004 Mar 9. Blood. 2004. PMID: 15010373 Free article. Clinical Trial.
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project. Baxter EJ, et al. Among authors: green ar. Lancet. 2005 Mar 19-25;365(9464):1054-61. doi: 10.1016/S0140-6736(05)71142-9. Lancet. 2005. PMID: 15781101
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Harrison CN, et al. Among authors: green ar. N Engl J Med. 2005 Jul 7;353(1):33-45. doi: 10.1056/NEJMoa043800. N Engl J Med. 2005. PMID: 16000354 Free article. Clinical Trial.
1,158 results